CoChat

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

Lebwohl, David, Anak, Özlem, Sahmoud, Tarek, Klimovsky, Judith, Elmroth, Ingrid, Haas, Tomas, Posluszny, Joseph, Saletan, Stephen, Berg, William · 2013 · Annals of the New York Academy of Sciences
Cited by 92

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Everolimus is a potent, oral inhibitor of the mammalian target of rapamycin (mTOR) that has been investigated in multiple clinical development programs since 1996. A unique collaboration between academic and pharmaceutical experts fostered research that progressed rapidly, with simultaneous indication findings across numerous tumor types. Initially developed for the prophylaxis of organ transplant rejection, everolimus has demonstrated efficacy and safety for the treatment of patients with various types of cancer (renal cell carcinoma, neuroendocrine tumors of pancreatic origin, and breast cancer) and for adult and pediatric patients with tuberous sclerosis complex. The FDA approval of everolimus for these diseases has addressed several unmet medical needs and is widely accepted by the medical community where treatment options may be limited. An extensive clinical development program is ongoing to establish the role of everolimus as monotherapy, or in combination with other agents, in the treatment of a broad spectrum of malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/nyas.12122

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 92

Metadata

Authors
Lebwohl, D., Anak, Ö., Sahmoud, T., Klimovsky, J., Elmroth, I., Haas, T., Posluszny, J., Saletan, S., & Berg, W.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2013-05-09
Volume
1291
Issue
1
Pages
14-32
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1900079465
Cited by
92
References
6
FWCI
5.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. https://app.cochat.ai/papers/10.1111/nyas.12122
The paper
Lebwohl, D., Anak, Ö., Sahmoud, T., Klimovsky, J., Elmroth, I., Haas, T., Posluszny, J., Saletan, S., & Berg, W. (2013). Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.12122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.